Study conduct in groups [Design Issues]

posted by ElMaestro  – Denmark, 2015-02-02 09:21 (3701 d 14:25 ago) – Posting: # 14347
Views: 26,382

Hi Smitha,

❝ If a Bioequivalence study has to be conducted in 2 groups (say 20 volunteers each), does the FDA or EMA require that all 40 volunteers be recruited into the study before Group 1 Period 1 dosing? :confused:


That's an interesting question. At least, I never gave it any thought, but of course that doesn't mean much.
If I get you right you are asking if you you need 40 signed ICF's before dosing your first subject. No guideline discusses it, I think.

I can't offer an answer, but I think I would play it safe. In a trial with 20 subject and 2 backups you would ordinarily have all 22 ICF's signed before the first subject is dosed. If the backups are needed the trial is in a sense having two groups, right? Only the second group is rather small, but in a sense it serves the same purposes: getting the desired number of subjects.
Also if you start a study when 20 ICFs are available and you cannot execute group 2 because you for some reason are running out of eligibles then all manners of GCP hell could ensue. Thus, I am leaning towards treating 20+20 like 20+2.

This is just one opinion and not a very qualified one. I hope others will chime in as I believe there might also be arguments for doing it the other way. So I will go make some popcorn and will watch this thread with interest.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,669 registered users;
19 visitors (0 registered, 19 guests [including 10 identified bots]).
Forum time: 23:46 CET (Europe/Vienna)

Facts are meaningless. You could use facts to prove
anything that’s even remotely true!    Homer Simpson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5